Pure Global

Effect of TPN171H on Spermatogenesis - Trial NCT05585931

Access comprehensive clinical trial information for NCT05585931 through Pure Global AI's free database. This Phase 1 trial is sponsored by Vigonvita Life Sciences and is currently Recruiting. The study focuses on Erectile Dysfunction. Target enrollment is 18 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT05585931
Phase 1
Recruiting
drug
Trial Details
ClinicalTrials.gov • NCT05585931
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Effect of TPN171H on Spermatogenesis
Evaluate the Acute Effects of a Single Oral Dose of TPN171H on Semen Function in Healthy Male Subjects in China

Study Focus

Erectile Dysfunction

TPN171H 10mg

Interventional

drug

Sponsor & Location

Vigonvita Life Sciences

Beijing, China

Timeline & Enrollment

Phase 1

Nov 15, 2022

Apr 01, 2023

18 participants

Primary Outcome

Effect on semen function,Seminal plasma exposure

Summary

This study is a phaseⅠstudy to determine the acute effects of TPN171H on semen function in
 healthy male subjects.

ICD-10 Classifications

Orgasmic dysfunction
Other disorders of penis
Other specified disorders of penis
Sexual dysfunction, not caused by organic disorder or disease
Testicular dysfunction

Data Source

ClinicalTrials.gov

NCT05585931

Non-Device Trial